 |
|
|
| |
Sustained Immune Control in HBeAg-Positive Chronic Hepatitis B Patients Who Switched From Long-Term Entecavir Therapy to Peginterferon Alfa-2a (40KD): 1-Year Follow-Up of the OSST Study
|
| |
| |
Reported by Jules Levin
AASLD 2013 Nov 1-5 Wash DC
M. Han,1 J. Jiang,2 J. Hou,3 D. Tan,4 Y. Sun,5 M. Zhao,6 Q. Ning;1 on behalf of the OSST study group
1Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 2The First Hospital, Fujian Medical University, Fuzhou, China; 3Nanfang Hospital, Nanfang Medical University, Guangzhou, China;4Xiangya Hospital, Central South University, Changsha, China; 5Tangdu Hospital, The Fourth Military Medical University, Xi'an, China; 6Shanghai Roche Pharmaceuticals Co., Ltd, Shanghai, China
|
| |
|
|
|
|
|
